Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS research · 2025-10-31

Clinical Trial Update: Avalglucosidase Alfa French Post-trial Access for Participants With Pompe Disease (PTA Avalglucosidase) [Phase 4]

View source ↗

Summary

Post-trial access update for avalglucosidase alfa in participants with Pompe disease from a Phase 4 trial; the study is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Avalglucosidase alfa (avalglucosidase alfa)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Glycogen Storage Disease Type II | Phase 4 | Status: ACTIVE_NOT_RECRUITING